Purpose: Nivolumab plus ipilimumab (NIVO + IPI) is a first-in-class combination immunotherapy for the treatment of intermediate- or poor (I/P)-risk advanced or metastatic renal cell carcinoma (mRCC). Currently, there are limited real-world data regarding clinical effectiveness beyond 12-24 months from treatment initiation. In this real-world study, treatment patterns and clinical outcomes were evaluated for NIVO + IPI in a community oncology setting.
View Article and Find Full Text PDFIntroduction Urinary incontinence, sexual dysfunction, and bowel dysfunction are well-recognized cancer survivorship outcomes affected by radical prostatectomy (RP) in the treatment of prostate cancer (PCa).The aim of this study was to audit the thoroughness of outpatient discussions and documentation of survivorship outcomes for patients who have undergone RP. Methods This was a retrospective audit of all 253 radical prostatectomies conducted at two tertiary-level Australian institutions (Monash Medical Centre and Alfred Hospital), over a five-year period between 2014 and 2018.
View Article and Find Full Text PDFMetagenomic sequencing has emerged as a transformative tool in infectious disease diagnosis, offering a comprehensive and unbiased approach to pathogen detection. Leveraging international standards and guidelines is essential for ensuring the quality and reliability of metagenomic sequencing in clinical practice. This review explores the implications of international standards and guidelines for the application of metagenomic sequencing in infectious disease diagnosis.
View Article and Find Full Text PDFBackground: Autosomal dominant polycystic kidney disease (ADPKD) is a common inherited condition; however, its relationship with renal cell carcinoma (RCC) remains unclear. This paper aims to establish the prevalence of RCC and its subtypes amongst ADPKD patients.
Methods: A database search was conducted to retrieve studies reporting RCC occurrence within ADPKD patients until July 2023.